Uy Ear
Stock Analyst at Mizuho
(2.47)
# 858
Out of 4,829 analysts
60
Total ratings
100%
Success rate
11.51%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Outperform | $51 | $20.71 | +146.26% | 1 | Apr 21, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $14.39 | +45.93% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $13.15 | +52.09% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.40 | +151.07% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $31.27 | +27.92% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $6.75 | +137.04% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $10.44 | +283.14% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $36.37 | +392.16% | 5 | May 17, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $17.52 | +19.86% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $9.98 | +130.46% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $120.43 | +16.25% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $154.14 | -74.05% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.29 | +675.19% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.70 | +328.57% | 2 | Mar 1, 2023 |
Tectonic Therapeutic
Apr 21, 2025
Initiates: Outperform
Price Target: $51
Current: $20.71
Upside: +146.26%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $14.39
Upside: +45.93%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $13.15
Upside: +52.09%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.40
Upside: +151.07%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $31.27
Upside: +27.92%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $6.75
Upside: +137.04%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $10.44
Upside: +283.14%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $36.37
Upside: +392.16%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $17.52
Upside: +19.86%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $9.98
Upside: +130.46%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $120.43
Upside: +16.25%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $154.14
Upside: -74.05%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.29
Upside: +675.19%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.70
Upside: +328.57%